Clinical Trial Detail

NCT ID NCT03788291
Title Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University of Rochester
Indications

CLL/SLL

chronic lymphocytic leukemia

Therapies

Acalabrutinib + Rituximab

Age Groups: adult senior

No variant requirements are available.